CX NEWS
ATTRACT trial results presented at CX
Suresh Vedantham Delegates heard yesterday the results of the ATTRACT randomised controlled trial, which showed that the addition of catheter-based intervention to anticoagulation failed to significantly decrease the occurrence of post-thrombotic syndrome [...]
CX audience homes in on grey area between drug-coated balloons and stents
Yesterday, delegates heard brand new data for drug-coated balloons (DCBs) in “wider use” scenarios such as challenging lesions; one-year results for a novel DCB; and late-breaking data on downstream coating effects of various DCBs. [...]
CX Venous Consensus Update: Take-home messages
The CX Venous Consensus Update—Plenary Programme took place on the first day of CX 2017 (Tuesday, 25 April). Stephen Black, member of the CX Programme Organising Board, summarises the take-home messages of this session. [...]
CX 2017: Peripheral Arterial Consensus highlights
The CX 2017 Peripheral Arterial Consensus Update Programme will focus on PATHWAYS OF CARE – whether to intervene, when and at what threshold, method and follow-up. "Over three days (25–27 April) there will be [...]
CX 2017: Acute Stroke Consensus highlights
Interventions in the aorta and manipulations in the aortic arch have become a “potential source of embolisation to the brain,” notes Roger Greenhalgh, Chairman of the CX Programme Organising Board. The Acute Stroke Consensus [...]
What makes CX so special?
Vascular and endovascular thought-leaders Andrew Holden, Thomas Zeller, Stephen Black, Ian Franklin, Nicholas Inston, Matt Thompson and Giovanni Torsello share their views on what makes CX so special. What makes CX so special for [...]